Register for our free email digests:
Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Writes for:
Latest From Andrew McConaghie
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Novavax Could Be The Next Biotech Winner In COVID-19 Vaccines
After years of setbacks, Novavax is on the cusp of success with its COVID-19 vaccine - but a rapid scale up of manufacturing and commercial operations will be a huge challenge.
Coronavirus Update: Pfizer CEO Thinks Vaccine Price Rise Likely Post-Pandemic
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.
Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal
Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.
Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.
CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’
While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.